JP2012524113A - ゲムシタビン構造に基づくプロドラッグおよびその合成方法と応用 - Google Patents

ゲムシタビン構造に基づくプロドラッグおよびその合成方法と応用 Download PDF

Info

Publication number
JP2012524113A
JP2012524113A JP2012506308A JP2012506308A JP2012524113A JP 2012524113 A JP2012524113 A JP 2012524113A JP 2012506308 A JP2012506308 A JP 2012506308A JP 2012506308 A JP2012506308 A JP 2012506308A JP 2012524113 A JP2012524113 A JP 2012524113A
Authority
JP
Japan
Prior art keywords
dicarboxylic acid
gemcitabine
acid
anhydride
dicarboxylic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012506308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524113A5 (enExample
Inventor
シュー，シャオシャ
リ，ガン
スン，チャンジュン
リ，ウェンバオ
Original Assignee
サンルゲン ファーマテック リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンルゲン ファーマテック リミテッド filed Critical サンルゲン ファーマテック リミテッド
Publication of JP2012524113A publication Critical patent/JP2012524113A/ja
Publication of JP2012524113A5 publication Critical patent/JP2012524113A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2012506308A 2009-04-21 2010-03-25 ゲムシタビン構造に基づくプロドラッグおよびその合成方法と応用 Pending JP2012524113A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2009100207167A CN101525361B (zh) 2009-04-21 2009-04-21 基于吉西他滨结构的前药及其合成方法及应用
CN200910020716.7 2009-04-21
PCT/CN2010/000372 WO2010121486A1 (zh) 2009-04-21 2010-03-25 基于吉西他滨结构的前药及其合成方法及应用

Publications (2)

Publication Number Publication Date
JP2012524113A true JP2012524113A (ja) 2012-10-11
JP2012524113A5 JP2012524113A5 (enExample) 2013-05-09

Family

ID=41093454

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012506308A Pending JP2012524113A (ja) 2009-04-21 2010-03-25 ゲムシタビン構造に基づくプロドラッグおよびその合成方法と応用

Country Status (7)

Country Link
US (1) US8653048B2 (enExample)
EP (1) EP2423215A4 (enExample)
JP (1) JP2012524113A (enExample)
CN (2) CN101525361B (enExample)
CA (1) CA2759474A1 (enExample)
IL (1) IL215792A0 (enExample)
WO (1) WO2010121486A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536954A (ja) * 2012-11-07 2015-12-24 ズカイ スオ 置換ゲムシタビンアリールアミド類似体
JP2016539956A (ja) * 2013-12-04 2016-12-22 杭州民生▲薬▼物研究院有限公司 ゲムシタビン誘導体、該誘導体を含む組成物及び該誘導体の製薬用途
JP2019508505A (ja) * 2016-03-14 2019-03-28 スフェラ ファーマ ピーブイティー リミテッドＳｐｈａｅｒａ Ｐｈａｒｍａ Ｐｖｔ． Ｌｔｄ． トリゴネリンベースの化合物

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101525361B (zh) * 2009-04-21 2010-11-17 济南圣鲁金药物技术开发有限公司 基于吉西他滨结构的前药及其合成方法及应用
CN102115485A (zh) * 2009-12-30 2011-07-06 济南圣鲁金药物技术开发有限公司 基于阿糖胞苷结构的前药及其合成方法及应用
CN102432654A (zh) * 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
WO2014078295A1 (en) 2012-11-13 2014-05-22 BoYen Therapeutics, Inc. Gemcitabine prodrugs and uses thereof
US10000521B2 (en) 2013-03-15 2018-06-19 Nucorion Pharmaceuticals, Inc. Substituted gemcitabine bicyclic amide analogs and treatment methods using same
US10463684B2 (en) 2014-01-29 2019-11-05 Board Of Regents, The Uneversety Of Texas System Nucleobase analogue derivatives and their applications
WO2015134334A1 (en) * 2014-03-03 2015-09-11 Suo Zucai Gemcitabine analogs
CN105001291B (zh) * 2014-04-15 2018-12-04 上海知萌生物医药科技有限公司 吉西他滨化学传递前药及其制备方法和应用
CN104910024B (zh) * 2015-05-12 2017-02-22 四川理工学院 一种驱油用表面活性剂
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
CN111836818B (zh) 2018-01-10 2023-10-31 纽科利制药公司 氨基磷(膦)酸缩醛和磷(膦)酸缩醛化合物
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
CN108329371B (zh) * 2018-03-06 2021-04-09 沈阳药科大学 白蛋白结合型吉西他滨前药及其合成和应用
AU2019258590B2 (en) * 2018-04-26 2022-09-08 NanoMed Holdings Pty Ltd Gemcitabine amphiphile prodrugs
EP3999519A4 (en) 2019-07-17 2023-08-16 Nucorion Pharmaceuticals, Inc. CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS
CN110845560B (zh) * 2019-11-21 2021-08-24 广东中科药物研究有限公司 苯丙氨酸酰胺化的核苷酸衍生物及其制备方法与应用
CN111298132B (zh) * 2020-02-22 2022-06-24 新乡医学院 一种树状分子吉西他滨自组装纳米前药及其制备方法和应用
EP4139319A4 (en) 2020-04-21 2024-06-19 Ligand Pharmaceuticals, Inc. BENZYLOXY-PHOSPH(ON)ATE COMPOUNDS
WO2021216427A1 (en) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041203A2 (en) * 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
CN101525361A (zh) * 2009-04-21 2009-09-09 济南圣鲁金药物技术开发有限公司 基于吉西他滨结构的前药及其合成方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
JP4352115B2 (ja) 1997-01-24 2009-10-28 クラヴィス・ファルマ・アーエスアー ゲムシタビン誘導体
EP1210354A1 (en) 1999-09-08 2002-06-05 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
GB0321613D0 (en) 2003-09-15 2003-10-15 Drug Discovery Lab As Compounds
US20050137141A1 (en) * 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
WO2006030217A2 (en) 2004-09-15 2006-03-23 Drug Discovery Laboratory As Drug conjugates of long chain fatty acid or ester moieties as protein binding prodrugs
PL1831237T3 (pl) 2004-12-17 2009-01-30 Lilly Co Eli Amidowy prolek gemcytabiny, kompozycje go zawierające oraz jego zastosowanie
NO322682B1 (no) 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
US20070225248A1 (en) 2006-03-21 2007-09-27 Clavis Pharma As Oral dosage forms of gemcitabine derivatives
US8114854B2 (en) 2006-06-21 2012-02-14 Eli Lilly And Company Crystalline forms of gemcitabine amide prodrug, compositions and use thereof
US20090068286A1 (en) * 2007-09-11 2009-03-12 Resprotect, Gmbh Method of treating cancer by administration of 5-substituted nucleosides
FR2922551B1 (fr) 2007-10-17 2009-12-25 Univ Claude Bernard Lyon Prodrogues phosphoesters de la gemcitabine comme agents anticancereux

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041203A2 (en) * 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
CN101525361A (zh) * 2009-04-21 2009-09-09 济南圣鲁金药物技术开发有限公司 基于吉西他滨结构的前药及其合成方法及应用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536954A (ja) * 2012-11-07 2015-12-24 ズカイ スオ 置換ゲムシタビンアリールアミド類似体
JP2016539956A (ja) * 2013-12-04 2016-12-22 杭州民生▲薬▼物研究院有限公司 ゲムシタビン誘導体、該誘導体を含む組成物及び該誘導体の製薬用途
JP2019508505A (ja) * 2016-03-14 2019-03-28 スフェラ ファーマ ピーブイティー リミテッドＳｐｈａｅｒａ Ｐｈａｒｍａ Ｐｖｔ． Ｌｔｄ． トリゴネリンベースの化合物

Also Published As

Publication number Publication date
CN101525361A (zh) 2009-09-09
CN102428093A (zh) 2012-04-25
EP2423215A4 (en) 2013-05-22
CN101525361B (zh) 2010-11-17
EP2423215A1 (en) 2012-02-29
US8653048B2 (en) 2014-02-18
WO2010121486A1 (zh) 2010-10-28
CA2759474A1 (en) 2010-10-28
US20120088908A1 (en) 2012-04-12
IL215792A0 (en) 2012-01-31

Similar Documents

Publication Publication Date Title
US8653048B2 (en) Prodrugs based on gemcitabine structure and synthetic methods and applications thereof
US10793543B2 (en) Selective C-KIT kinase inhibitor
CN103588713B (zh) 多靶点型乌苯美司前药衍生物及其制备方法和用途
JP7066728B2 (ja) Ｃ型肝炎ウイルスの治療のためのヌクレオチドヘミ硫酸塩
TWI466870B (zh) Anti - tumor efficacy enhancer
JP6769000B2 (ja) ４’−チオヌクレオシドの新規な化合物、並びにその調製方法、その医薬組成物及びその用途
JP6538656B2 (ja) ５’−ヌクレオチダーゼ阻害剤およびその治療的使用
KR20120083492A (ko) 신규 5-플루오로우라실 유도체
WO2013044811A1 (zh) 吉西他滨酰胺衍生物及其制备方法和用途
CN104961786B (zh) 基于吉西他滨结构的前体药物及其应用
ES2385850T3 (es) Potenciador de radioterapia
CN112321604A (zh) 大环类jak2抑制剂及其应用
CN102066362A (zh) 二氢吲哚酮衍生物
CN103130854A (zh) 维生素e琥珀酸酯化吉西他滨前药及应用
WO2011143864A1 (zh) 抗癌用化合物及制备方法
TW201734028A (zh) 抑制癌症及病毒之化合物
WO2011079501A1 (zh) 基于阿糖胞苷结构的前药及其合成方法及应用
CN113135909A (zh) Dpd抑制剂及其制备方法、药物组合物和用途
CN112279863A (zh) Hsp90抑制剂与喜树碱衍生物的偶联物及其制备方法与应用
CN101787066B (zh) 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
CN101787065B (zh) 阿糖胞苷前药衍生物及其在抗癌抗肿瘤中的用途
CN110016026A (zh) 一类具有抗肿瘤活性的嘧啶并吡啶酮类化合物、制备方法和用途
CN109422799A (zh) 多烯紫杉醇抗肝癌靶向前药及其药用用途
WO2011113173A1 (zh) 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
Yu et al. Design, Synthesis and Evaluation of a Novel Teoptinib Derivative as an Effective Anti-hepatocellular Carcinoma Agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130321

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141118